The date format must match "dd.mm.YYYY"
Informative studies are still lacking for the comparison with the currently used risk-based strategy.
The first drug of a new drug class can reduce the number of headache days if other prophylactic medications have failed or have not been an option.
Commissioned by the Federal Ministry of Health, the Institute searched for studies on vaginal (“natural”) birth and assessed them. The guideline group appreciates the high quality of the reports.
Only few study participants received approval-compliant treatment. Therefore, the extent of added benefit is non-quantifiable.
The focus is on international HTA activities. Further topics: 7 years of AMNOG, big data, studies on medical devices, and other topics. Available online at IQWiG as a PDF or as a print version.
This combination showed advantages in survival and recurrence. An added benefit was not proven for another combination used in advanced disease.
From January 2019, Jens Flintrop will be Head of the Communications Unit. After many years as a journal editor, he became press officer at the Westfalen-Lippe Association of SHI Physicians.
Following a negative G-BA decision due to a lack of data in 2013, the drug manufacturer now presented a suitable, albeit very short study.
For psoriasis, it has been known since 2007 that UV light therapy should be combined with brine baths. New data have now shown this also for atopic eczema.
Even eleven years after the first benefit assessment, the evidence base remains inadequate. The hopes to be able to close gaps in knowledge were disappointed when PREFERE failed in 2016 due to a lack of interest.
There are no suitable studies for the benefit assessment of screenings of the general population. Thorough accompanying evaluation is required for hepatitis C screening of risk groups.
About 1000 experts are expected to participate in the annual meeting of Health Technology Assessment International (HTAi) in Cologne. IQWiG is coordinating the scientific Programme.
The treatment effect on disease-free survival is not large enough to derive an effect on overall survival from it.
Compliance of pharma companies is relatively good, but very poor for university research groups. Research funders should make allocation of further funding dependent on data transparency.
Communicating evidence so that it reaches decision-makers, despite persistent prejudice and interest-driven interference: How does that work? We will discuss this on 23 and 24 November.
IQWiG still sees no basis for introducing a screening programme. There were neither comments on the preliminary report nor other new findings.
New guidelines change the results of the final report versus the preliminary report: Stronger focus, among other things, on the avoidance of hypoglycaemia by means of modern technologies.
TAILORx is the first available study with long-term follow-up suitable for the assessment. The Oncotype DX test apparently identifies women who can omit chemotherapy.
The treatment has been used in hospitals for over 20 years, and more than 100 studies have been completed worldwide. But manufacturers and researchers are concealing a large proportion of the results.
Less pain in stiff shoulders and improved mobility after total knee replacement – but the final report does not confirm greater benefit in rotator cuff tears.
+49 221 35685-151
Dr. Anna-Sabine Ernst
+49 221 35685-153
+49 221 35685-158
To save your search result, please copy the link below and paste it into a new tab/window.